Semaglutide News and Research

Latest Semaglutide News and Research

Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes

Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.

17 Feb 2010

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma. Data will be presented as part of a poster session for the 1st Systemic Sclerosis World Congress to be held in Florence, Italy, February 11 to 13, 2010.

11 Feb 2010

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reported today its sales for the fourth quarter and full year 2009.

1 Feb 2010

MPI Research lauds FDA's current guidance on abuse potential of drugs

On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA’s current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.

30 Jan 2010

FDA approves Victoza to treat type 2 diabetes in some adults

The U.S. Food and Drug Administration today approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults.

27 Jan 2010

FDA approves Novo Nordisk's Victoza for type 2 diabetes

Novo Nordisk, a global healthcare company, announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

27 Jan 2010

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.

13 Jan 2010

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

Pharmaron Holdings acquires Bridge Laboratories China

Pharmaron Holdings Limited, today announced it completed the acquisition of Bridge Laboratories China. Bridge Laboratories China is the leading contract research organization (CRO) in China providing western standard GLP-compliant toxicology services to pharmaceutical and biotech companies from around the world. With this acquisition, Pharmaron becomes the first integrated CRO in China supporting clients with drug discovery and development processes in support of IND filings. This strategic acquisition strengthens Pharmaron's leading position in the fast-growing, highly dynamic pharmaceutical CRO industry.

12 Jan 2010

LAB Research completes research and development program that involves pulmonary monitoring system

LAB Research Inc. ("LAB" or "LAB Research"),a Canadian-based global non-clinical contract research organization, today announced that it recently completed a research and development program that involves real time quantitative pulmonary monitoring of non-human primates using wireless telemetry technology.

8 Jan 2010

Liraglutide FDA feedback expected within weeks, says Novo Nordisk

Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1 analogue, is expected within weeks.

30 Dec 2009

CSC completes a Series B financing round

California Stem Cell, Inc. (CSC), a leading stem cell company, announced that it has completed a Series B financing round with private investors. The financing will enable the company to support the advancement of its therapeutic products to human clinical trials, as well as the generation and distribution of its tools to aid in stem cell research and drug discovery.

21 Dec 2009

KVCI completes acquisition of former AAIPharma bioanalytical division

Kansas Venture Capital, Inc. (KVCI) has acquired the former AAIPharma bioanalytical division from ZeeCRO Inc. With its 30-year track record of developing entrepreneurial companies, KVCI will grow the bioanalytical business through organic and acquisition strategies to provide best-in-class analytical services for both the pharmaceutical and life sciences sectors.

18 Dec 2009

STERIPLEX HC kills MRSA and other pathogens in record time

STERIPLEX® Health Care (HC) is a new Sterilant/Sporicide, Tuberculocide, and Bactericide, which has recently received Federal EPA Registration. STERIPLEX® HC sets new standards, killing MRSA, spores and other pathogens in a fraction of the time of competing products while remaining safe to people and the environment.

18 Dec 2009

Ocimum Biosolutions ranked 42nd on the Deloitte Technology Fast 500 Asia Pacific 2009

Ocimum Biosolutions, a leading integrated genomics company, today announced that it ranked 42nd on the Deloitte Technology Fast 500 Asia Pacific 2009, a ranking of the 500 fastest growing technology companies in Asia Pacific. Rankings are based on percentage revenue growth over three years. In addition to ranking on Deloitte’s Technology Fast 500, Ocimum ranked fourth on the Technology Fast 50 India Program, which is a ranking of the 50 fastest growing technology firms in India.

18 Dec 2009

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors.

18 Dec 2009

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.

17 Dec 2009

Repligen receives $731,000 to support ongoing development of new treatments for Friedreich's ataxia

Repligen Corporation today announced that the Company has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich's ataxia from the Muscular Dystrophy Association (MDA).

16 Dec 2009

CSC's stem cell-derived motor neuron product for SMA receives FDA orphan drug designation

California Stem Cell, Inc. (CSC) and Families of Spinal Muscular Atrophy (FSMA) announced today that the FDA has granted orphan drug designation to MOTORGRAFT™, a stem cell-derived motor neuron product, for the treatment of Spinal Muscular Atrophy (SMA).

9 Dec 2009

Absorption Systems opens renovated AAALAC-accredited GLP surgical suite for medical device testing

Absorption Systems, a leader in testing drugs for ADMET (absorption, distribution, metabolism, excretion and toxicity), today introduced an extensively renovated surgical suite for preclinical medical device testing at the company’s facility in San Diego, CA. Absorption Systems has long been recognized as a leader in drug testing and is experiencing increased demand for its medical device testing services as well.

4 Dec 2009

Semaglutide News and Research

Latest Semaglutide News and Research

Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Ipsen reports consolidated group sales of €1,032.8M for 2009

MPI Research lauds FDA's current guidance on abuse potential of drugs

FDA approves Victoza to treat type 2 diabetes in some adults

FDA approves Novo Nordisk's Victoza for type 2 diabetes

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Pharmaron Holdings acquires Bridge Laboratories China

LAB Research completes research and development program that involves pulmonary monitoring system

Liraglutide FDA feedback expected within weeks, says Novo Nordisk

CSC completes a Series B financing round

KVCI completes acquisition of former AAIPharma bioanalytical division

STERIPLEX HC kills MRSA and other pathogens in record time

Ocimum Biosolutions ranked 42nd on the Deloitte Technology Fast 500 Asia Pacific 2009

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Repligen receives $731,000 to support ongoing development of new treatments for Friedreich's ataxia

CSC's stem cell-derived motor neuron product for SMA receives FDA orphan drug designation

Absorption Systems opens renovated AAALAC-accredited GLP surgical suite for medical device testing

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Semaglutide News and Research

Latest Semaglutide News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in